A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa

Summary

The main objective of this study is to determine if NAV-240 works more effectively than a dummy treatment (placebo) for participants with moderate-to-severe HS. The main endpoint of this study is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 16, meaning at least a 75% reduction in inflamed skin bumps (abscess and inflammatory nodule (AN) count) with no increase in number of abscesses or draining tunnels (channels under the skin that leak fluid or pus) compared to the baseline (start of the study).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Hidradenitis Suppurativa (HS)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 70 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Navigator Medicines, Inc.

Last updated on ClinicalTrials.gov

July 22, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites